Abstract
The increasing resistance of Mycobacterium tuberculosis to the existing drugs has alarmed the worldwide scientific community. In an attempt to overcome this problem computer-aided drug design has provide an extraordinary support to the different strategies in drug discovery. There are around 250 biological receptors such as enzymes that can be used in principle, for the design of antituberculosis compounds that act by a specific mechanism of action. Also, there more than 5000 compound available in the literature, and that constitute important information in order to search new molecular patterns for the design of new antituberculosis agents. The purpose of this paper is to explored the current state of drug discovery of antituberculosis agents and how the different strategies supported by computeraided drug design methods has influenced in a determinant way in the design of new molecular entities that can result the future antituberculosis drugs.
Keywords: Structure based-drug design, ligand based-drug design, enzymatic inhibitors, 3D-QSAR methodologies, graph-theoretical approaches, computer-aided drug design, antituberculosis, MDR-TB, Artificial Neural Networks (ANN), ANTI-TB AGENTS, CoMSIA methods, CoMFA methods, MIC, Heterogeneous Series, Mycobacterium tuberculosis, QSPR, QSTR, Multiple Linear Regression, Hydropathic Interactions, CP-MLR
Current Pharmaceutical Design
Title: Current Pharmaceutical Design of Antituberculosis Drugs: Future Perspectives
Volume: 16 Issue: 24
Author(s): Alejandro Speck-Planche, Marcus Tulius Scotti and Vicente de Paulo-Emerenciano
Affiliation:
Keywords: Structure based-drug design, ligand based-drug design, enzymatic inhibitors, 3D-QSAR methodologies, graph-theoretical approaches, computer-aided drug design, antituberculosis, MDR-TB, Artificial Neural Networks (ANN), ANTI-TB AGENTS, CoMSIA methods, CoMFA methods, MIC, Heterogeneous Series, Mycobacterium tuberculosis, QSPR, QSTR, Multiple Linear Regression, Hydropathic Interactions, CP-MLR
Abstract: The increasing resistance of Mycobacterium tuberculosis to the existing drugs has alarmed the worldwide scientific community. In an attempt to overcome this problem computer-aided drug design has provide an extraordinary support to the different strategies in drug discovery. There are around 250 biological receptors such as enzymes that can be used in principle, for the design of antituberculosis compounds that act by a specific mechanism of action. Also, there more than 5000 compound available in the literature, and that constitute important information in order to search new molecular patterns for the design of new antituberculosis agents. The purpose of this paper is to explored the current state of drug discovery of antituberculosis agents and how the different strategies supported by computeraided drug design methods has influenced in a determinant way in the design of new molecular entities that can result the future antituberculosis drugs.
Export Options
About this article
Cite this article as:
Speck-Planche Alejandro, Tulius Scotti Marcus and de Paulo-Emerenciano Vicente, Current Pharmaceutical Design of Antituberculosis Drugs: Future Perspectives, Current Pharmaceutical Design 2010; 16 (24) . https://dx.doi.org/10.2174/138161210792389289
DOI https://dx.doi.org/10.2174/138161210792389289 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice
Current Pharmaceutical Design Natural Resins and Bioactive Natural Products thereof as Potential Anitimicrobial Agents
Current Pharmaceutical Design Potential Therapeutic Agents from the Red Sea Organisms
Medicinal Chemistry Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
Current Respiratory Medicine Reviews Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Uncovering Drug Mechanism of Action by Proteome Wide- Identification of Drug-Binding Proteins
Medicinal Chemistry Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Development and Implementation of the DHAPP Military eHealth Information Network System
Current HIV Research Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Glycine Rich P-loop Motif in Deoxyuridine Pyrophosphatase
Current Protein & Peptide Science Design, Synthesis and Evaluation of Thiourea Derivatives as Antimicrobial and Antiviral Agents
Letters in Drug Design & Discovery Targeting the Mannose Receptor with Mannosylated Subunit Vaccines
Current Medicinal Chemistry Shikimate Kinase: A Potential Target for Development of Novel Antitubercular Agents
Current Drug Targets Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Current Topics in Medicinal Chemistry Understanding Mass Spectrometry-based Global Mycobacterial Lipidomics
Current Molecular Medicine Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry Preliminary Studies on Ligand-based Design and Evaluation of New Mycobacterial ATP Synthase Inhibitors
Current Drug Therapy